



Scheme Update – ACCC condition precedent satisfied

Brisbane, Australia, 18 July 2022 – ResApp Health Limited (ASX:RAP) (**ResApp**) provides the following update on the proposed scheme of arrangement with Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) under which it is proposed that Pfizer will acquire 100% of shares in ResApp (the **Scheme**) for A\$0.146 per share in cash.

ResApp is pleased to announce that the Australian Competition and Consumer Commission (**ACCC**) has advised that after considering the information provided by the parties it does not intend to conduct a public review of the proposed acquisition pursuant to section 50 of the *Competition and Consumer Act 2010* (Cth). Accordingly, the ACCC condition precedent in clause 3.1(a)(i) of the scheme implementation deed has been satisfied.

The implementation of the Scheme is still subject to satisfaction of other remaining conditions, including the approval by the ResApp shareholders at the Scheme meeting scheduled for 19 August 2022, and Court approval.

Recommendation of the ResApp Board

ResApp's directors unanimously recommend that ResApp shareholders vote in favour of the Scheme, in the absence of a Superior Proposal¹ and subject to the Independent Expert continuing to conclude that the Scheme is in the best interest of ResApp shareholders. Subject to those same qualifications, the directors intend to vote all ResApp shares held by or controlled by them in favour of the Scheme.

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

¹ As defined in the amended and restated scheme implementation deed announced on ASX on 14 June 2022.



Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the Managing Director of ResApp Health.